Linking Atrial Fibrillation with Alzheimer’s Disease: Epidemiological, Pathological, and Mechanistic Evidence

Ihara, Masafumi; Washida, Kazuo

doi:10.3233/jad-170970

Cited by 66 publications

(58 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We provide an approach to interpret the data from mechanistic studies based on microbiome. The microbiome features revealed a close association of AF with neurodegenerative diseases as well as cancers, which was supported by prior studies showing that AF had correlation with AD and PD 52, 53 , and AF patients had relatively higher risks of several cancers including lung cancer and CRC 54, 64 . We also observed that microbiome features of SLE and CML were highly similar.…”

Section: Discussionsupporting

confidence: 75%

The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for human complex diseases

Sun

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 75%

The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for human complex diseases

Sun

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…The incidence of SS has been reported to be related to sheath management, anticoagulation strategy, lesion site, ablation energy source, and intra‐cardiac cardioversion 41 . A previous report suggested that the SS was associated with the development of dementia and poor neuropsychological prognosis 42 . In addition, brain biopsy results from animal model studies showed that even healed lesions, based on MRI findings, leave behind evidence of cerebral ischaemic injury 43 .…”

Section: Discussionmentioning

confidence: 99%

Peri‐procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta‐analysis

Mao

Wang

Huang

2020

Pacing Clinical Electrophis

View full text Add to dashboard Cite

BACKGROUND: Studies indicate that uninterrupted anticoagulation is superior to interrupted anticoagulation in the periprocedural period during catheter ablation of atrial brillation and has better thromboembolic and hemorrhagic outcomes. Conversely, the few studies addressing the safety and e cacy of interrupted direct oral anticoagulant regimens during catheter ablation of atrial brillation are limited by small samples, short follow-up periods, rare events, and variable outcomes. The purpose of this metaanalysis was to compare interrupted and uninterrupted direct oral anticoagulation during catheter ablation of atrial brillation. METHODS: A systematic search into PubMed, EMBASE, and the Cochrane databases were performed and ve studies were selected that directly that directly compared interrupted versus uninterrupted anticoagulation before ablation and reported procedural outcomes and embolic and bleeding events. The primary outcome of the study was major adverse cerebrocardiovascular events which was a composite of stroke/ transient ischemic attacks and major bleedings, total bleeding which was a composite of major and minor bleedings and silent cerebral events. RESULTS The meta-analysis included 840 patients with uninterrupted anticoagulation and 938 patients with interrupted anticoagulation. Median follow-up was 30 days. Baseline parameters were similar between groups. Activated clotting time before rst heparin bolus was signi cantly longer with uninterrupted anticoagulation (P=.006), whereas mean activated clotting time was similar between the 2 groups (P=.19). Total heparin dose needed was signi cantly higher with interrupted anticoagulation (mean,-1.61; 95% CI,-2.67 to-0.55; P=.003). Mean procedure time did not vary between groups (P=.81). Overall complication rates were low, with similar major adverse cerebrocardiovascular event (P=.40) and total bleeding (P=.55) rates between groups. Silent cerebral events were signi cantly more frequent with interrupted anticoagulation (log odds ratio,-0.90; 95% CI,-1.59 to-0.22; P<.01; I 2 , 33%). Rates of major bleeding, minor bleeding, pericardial effusion, cardiac tamponade, and puncture complications were similar between groups. CONCLUSIONS Uninterrupted anticoagulation during atrial brillation ablation has similar bleeding event rates, procedural times, and mean activated clotting times as interrupted anticoagulation, with fewer silent cerebral events.

show abstract

“…Persistent AF reduces cardiac output and may lead to chronic cerebral hypoperfusion and hypoxia, which may impair the clearance and promote the accumulation of amyloid-beta peptides in cerebral vessels, thus leading to cerebral amyloid angiopathy and contributing to the onset of Alzheimer’s disease (AD) [ 37 – 39 ]. However, this hypothesis has been investigated by very few studies, among which one study examined the cognitive function and cerebral blood flow velocity in the major brain arteries in 187 patients with heart failure, out of which 32% had a history of AF [ 40 ].…”

Section: Association Of Atrial Fibrillation With Cognitive Decline Anmentioning

confidence: 99%

Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review

Ding

Qiu

2018

Curr Epidemiol Rep

View full text Add to dashboard Cite

Purpose of ReviewAtrial fibrillation (AF) and dementia are both prevalent diseases in aging societies, which exert a great economic burden worldwide. Although a handful of epidemiologic studies have indicated that AF is independently associated with faster cognitive decline and a higher risk of dementia, there is still a lack of comprehensive understanding of the observed association. In this review, we summarize evidence from major epidemiologic studies concerning AF-related cognitive decline and dementia, the potential mechanisms underlying their association, and the cognitive benefits of treatment options.Recent FindingsA large majority of population-based longitudinal studies have consistently shown an independent association of AF with cognitive decline and dementia with varying effect sizes, depending on the age of the study population and the presence of clinical stroke. The underlying pathways linking AF to cognitive phenotypes may involve systemic inflammation, cerebral hypoperfusion, and cerebral small vessel disease and microemboli. However, current evidence is insufficient to support the potential benefits of AF treatment in reducing risk of cognitive decline and dementia.SummaryCurrent epidemiologic research suggests that AF contributes to cognitive decline and dementia, independent of a history of stroke. Further work is warranted to elucidate the potential mechanisms underlying this association, and more well-designed studies are needed to explore the possible cognitive benefits of different therapeutic options in patients with AF.

show abstract

Linking Atrial Fibrillation with Alzheimer’s Disease: Epidemiological, Pathological, and Mechanistic Evidence

Cited by 66 publications

References 60 publications

The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for human complex diseases

The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for human complex diseases

Peri‐procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta‐analysis

Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review

Contact Info

Product

Resources

About